Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
Launched by HAAGLANDEN MEDICAL CENTRE · May 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SPARTA study is a research project happening in the Netherlands that aims to find out the best ways to treat patients with a specific type of bleeding in the brain called aneurysmal subarachnoid hemorrhage. This bleeding is usually caused by a burst blood vessel in the brain known as an aneurysm. The study will compare two main treatment methods: surgery and a less invasive approach called endovascular treatment. Researchers will also look at how much these treatments cost and what factors might influence a patient’s recovery.
To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of subarachnoid hemorrhage, with a specific aneurysm identified as the cause within the last six months. Participants will be asked to give their written consent to join the study. It’s important to note that the study is currently recruiting participants, and those who are fluent in Dutch are eligible. By joining, participants can help researchers better understand how to improve care for future patients facing this serious condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of subarachnoid haemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan)
- • Intracranial aneurysm proven within 6 months to be the cause of subarachnoid haemorrhage
- • Age 18 years or over at presentation.
- • Written informed consent
- Exclusion Criteria:
- • Subarachnoid haemorrhage deemed most likely of 'perimesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- • Subarachnoid haemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- • Diagnosis of intracerebral arteriovenous malformations or dural arteriovenous fistula.
- • No diagnosis of intracranial aneurysm at 6 months after onset of symptoms.
- • Not mastering the Dutch language
About Haaglanden Medical Centre
Haaglanden Medical Centre is a leading healthcare institution in the Netherlands, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on collaboration and excellence, the centre integrates clinical practice with cutting-edge research, focusing on a wide range of therapeutic areas. Haaglanden Medical Centre is committed to ensuring the highest ethical standards and regulatory compliance in its research initiatives, fostering an environment that promotes scientific inquiry and enhances the quality of healthcare delivery. Through its multidisciplinary approach and state-of-the-art facilities, the centre aims to contribute significantly to the development of new treatments and therapies for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, , Netherlands
Utrecht, , Netherlands
Maastricht, , Netherlands
Nijmegen, , Netherlands
Amsterdam, , Netherlands
Den Haag, , Netherlands
Patients applied
Trial Officials
Wouter Moojen, MD, PhD
Principal Investigator
Haaglanden Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported